BioCity Biopharma

🚀 Building a website? Start with reliable WordPress hosting from MilesWeb →

Business news, market intelligence, and global industry analysis.

The Latest

GoldStone Resources (AIM: GRL) shares jump as Persistence Gold takes 21% stake in AIM miner

Nexsen (ASX: NXN) jumps as StrepSure validation path sharpens

Novartis agrees $1.5bn Myricx Bio deal as ADC platform race intensifies

Knights Group revenue jumps 28% as KGH organic growth accelerates to 12%

Kidney and urinary disorders Understanding major conditions, terminology, and their role in human health

BioCity’s SC0062 secures second breakthrough therapy designation in China for diabetic kidney disease

BioCity Biopharma’s ETA-selective SC0062 earns second Breakthrough Therapy Designation in China for diabetic kidney disease, reinforcing its CKD potential.

μFR system
αvβ6-integrin
α4β7 integrin
Zywie Ventures
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynga
Zynext Ventures USA LLC
Zynext Ventures

June 26, 2025